PERSISTENCE OF VALVULOPATHY IN THE CAMELLIA-TIMI 61 TRIAL OF LORCASERIN IN OBESE OR OVERWEIGHT PATIENTS AT INCREASED CARDIOVASCULAR RISK

Lorcaserin, a serotonin 2C receptor agonist, recently demonstrated sustained weight loss without an increased risk of cardiovascular (CV) events or valvulopathy in obese or overweight pts at high CV risk. Here we evaluate the persistence of valvulopathy measures. The CAMELLIA-TIMI 61 trial